PHILADELPHIA--(BUSINESS WIRE)—October 11, 2018—Context Therapeutics today announced Phase 1 data for its investigational new drug, Apristor® (Onapristone extended release), an oral progesterone receptor antagonist that is being developed for progesterone receptor-positive (PR+) cancers. 

PHILADELPHIA, PA--(BUSINESS WIRE)— Context Therapeutics, a clinical stage biopharmaceutical company dedicated to the treatment of hormone driven cancers, today announces it has signed multiple research collaborations to further understand the role of progesterone receptor (PR) signaling and its blockade to overcome resistance mechanisms underlying metastatic breast cancer (mBCa).

PHILADELPHIA, Pa.--(BUSINESS WIRE)—Context Therapeutics, a clinical-stage biopharmaceutical company focused on hormonally-driven cancers, announced that CEO Martin Lehr is a semifinalist for Ernst, & Young’s (EY) 2018 Entrepreneur of the Year for the Philadelphia region.